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A B S T R A C T 
The prognostic for metastatic melanoma is very poor when treated with standard cytotoxic chemotherapies 
and it is often refractory to check point inhibitors and/or molecular targets. In this context the development 
of new treatments with better efficacy and safety profiles is highly desirable. Based on our successful 
experience applying suicide and immune gene therapy in a veterinary clinical setting, we are proposing its 
translation to human patients. We are presenting here the first-in-human safety assay of this approach. We 
report two cases of refractory metastatic melanoma. The first-one was a 27-years-old pharyngeal mucosal 
melanoma patient with a primary tumor in his left tonsil. Despite transient slowing down, the disease 
successively progressed to radiotherapy, radical surgery, ipilimumab, nivolumab, imatinib and 
temozolomide.The second-one was a 72-years-old malignant melanoma patient with a primary tumor in his 
left hallux. Despite transient slowing down, the disease successively progressed to hallux amputation, 
inguinal lymphadenectomy, radiotherapy, interferon-alpha, ipilimumab, pembrolizumab and 
temozolomide. The proposed treatment included local intratumoral suicide gene therapy concomitant with 
a subcutaneous vaccine composed by allogeneic tumor extracts and liposomes with plasmids bearing IL-2 
and GM-CSF genes. The treatment was safe: the only side effects were from mild to moderate and 
manageable: pyrexia, swelling of the injected tumor and partial hair loss (alopecia). Due to disease 
progression both patients were withdrawn from the study before completing the complete series of 
interventions. These preliminary data encourage the completion of further clinical trials to establish the 
possible clinical benefit of the proposed approach. 
 
 
                                             © 2020 Gerardo C. Glikin. Hosting by Science Repository. All rights reserved  
Introduction 
 
Malignant melanoma is the most destructive and fatal variety of skin 
cancer with a global estimate of 288,000 new cases and 61,000 deaths in 
2018 [1]. When early diagnosed at the primary site, most of cutaneous 
melanomas can be surgically excised and the disease definitely cured. 
Conversely, the prognostic for advanced or metastatic melanoma is very 
poor when treated with standard cytotoxic chemotherapies [2]. Due to 
the meager results obtained by these treatments, emergent new drugs 
were adopted for treatment of advanced melanoma: (i) monoclonal 
antibodies like ipilimumab, pembrolizumab and nivolumab and (ii) 
small molecules targeting different regulatory pathways like 
vemurafenib, trametinib, encorafenib and dabrafenib [3-5]. 
Unfortunately, these new treatments present a high rate of adverse 
effects and increase overall survival only in a limited number of patients. 
Other approaches, including intratumoral immunotherapies with diverse 
mechanisms of action such as non-oncolytic viral therapies (PV-10 and 
toll-like receptor 9 agonists) and oncolytic viral therapies (T-Vec, 
CAVATAK and HF10), are currently tested with promising results in 
clinical trials alone or in combination with checkpoint inhibitors [6].  
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Mucosal melanoma is an infrequent sort of malignant melanoma, 
representing only about 1.3% of melanoma cases. It is different from 
melanomas appearing in other places of the body and treatment options 
are very limited [7]. The rich lympho-vascular supply of the mucous 
membranes promoting early spread and metastasis of mucosal 
melanoma poses unresolved challenges and the urgent need for effective, 
safe and accessible therapies. Despite the different biology and because 
there are few specific studies, mucosal melanoma patients are usually 
treated in the same way than those bearing cutaneous melanoma, but 
with poorer outcomes [8]. 
 
Based on successful results obtained treating malignant mucosal 
melanoma in a veterinary clinical setting and aiming a translational 
objective, we planned a phase I clinical trial for human patients with 
advanced melanoma: “Suicide plus immune gene therapy for advanced 
melanoma” (NCT03338777) [9-11]. The main aim of this study was to 
evaluate the safety of combined gene therapies in melanoma patients. 
This treatment combines the high local cytotoxicity of the suicide HSV 
thymidine kinase gene system (HSVtk) associated to the prodrug 
ganciclovir (GCV) with the immune stimulation of interleukin-2 (hIL-2) 
and immune amplification of granulocyte and macrophage colony 
stimulating factor (hGM-CSF) in the presence of tumor antigens. The 
proposed scheme consists in the periodic intra/peritumoral application 
of plasmid DNA:cationic lipid complexes (lipoplexes) containing the 
HSVtk gene, co-administered with the prodrug GCV, and subcutaneous 
injections (far from melanoma lesions) of a vaccine produced with 
formolized allogeneic melanoma extracts combined with lipoplexes 
carrying the hIL-2 and hGM-CSF genes (Table 1). 
 
Table 1: Proposed treatment scheme. 
Agent (mg/ml) Volume (ml) Way Schedule (week) Cycle 
psCMVtk (1.0) + GCV (12.5) depending on 
tumor accessible surface or volume 
Min: 0.5 
Max: 2.0 
Intra-/peri-tumoral 1, 2, 3, 4, 5, 7, 9, 11, 13, 15 
10 rounds or until limiting 
toxicity or progression 
psCMVhIL-2 (0.5) + psCMVhGM-CSF (0.5) 
+ allogeneic tumor extract 
1.0 Sub-cutaneous vaccine 1, 2, 3, 4, 5, 7, 9, 11, 13, 15 
10 rounds or until limiting 
toxicity or progression 
#Patients start with a minimum 0.5 ml (weeks 1 and 2). Starting the 3rd week, the maximal doses (according the tumor burden) are applied. Follow-up until 
week 30. 
*Each vaccine containing 0.5 mg psCMVhIL-2 + 0.5 mg psCMVhGM-CSF + 0.25 ml formolized allogenic tumor extracts. 
 
Every plasmid was constructed using the same psCMV backbone and 
the corresponding gene and was amplified, purified and supplied by 
GenScript (Piscataway, NJ, USA) with the following specifications: 
≥95% supercoiled, ≤0.005 EU/μg endotoxin, animal-free [12]. Plasmids 
were provided at 2.0 mg/ml in sterile phosphate-buffered saline. 
DMRIE/DOPE liposomes, lipoplexes, allogeneic tumor extracts and 
tumor vaccines were prepared as previously described [10-12]. This 
phase I clinical trial was approved by the Ethics Committee for Research 
Protocols of the Italian Hospital of Buenos Aires (Argentina) and all the 
patients signed the Informed Consent before being recruited. Within the 
frame of this study we treated two patients with very advanced metastatic 
melanoma, for testing the feasibility of the treatment scheme and for 






A 26-year-old man presented in March 2017 with pain sore on his left 
tonsil due to an unresectable, stage IV pharyngeal mucosal malignant 
melanoma [13]. 
 
I Previous Management 
 
• March 2015: The patient 1 was diagnosed pharyngeal mucosal 
malignant melanoma in the left tonsil with cervical N3 
involvement and non-mutated BRAF V600. 
• June 2015: He received radiotherapy (4200 cGy) and started 
weekly carboplatin/paclitaxel chemotherapy. 
• September 2015, radical left cervical excision evidenced 2 
compromised lymph nodes (1 capsule disrupted). 
• December 2015: Due to disease progression, he started with 
ipilimumab treatment. 
• April 2016: In the absence of response, a disease spread was found 
at lungs, lymph nodes and bones and treatment with nivolumab 
started. 
• Again, the disease was refractory to treatment. The surgery of a 
metastatic lesion at the T3 vertebral body was followed by 
radiotherapy. 
• September 2016, the mutated c-KIT (CD 117) at exon 11 allowed 
treatment with imatinib that also failed in controlling the disease.  
• January 2017: Because progression of bone metastases, he was 
treated with temozolomide but again the tumor control failed. 
• April 2017: Due to the poor response to all the available treatments, 
the patient accepted to enter the suicide plus immune gene therapy 
protocol and signed the informed consent. The 18FDG-PET/CT 
imaging previous to recruitment displayed pharyngeal 
hypermetabolic compromise with secondary multiple lymph node, 
bilateral pulmonary, hepatic and osseous, as well as glandular 
(right submaxillary and adrenal, thyroid and pancreas) and 
muscular (left leg) high metabolic activity. 
 
II Treatment Course 
 
• May 2017: The patient received four weekly applications of 
subcutaneous vaccine (in the arm) and intralesional suicide gene 
therapy (in the cervical mass). As specified in (Table 1), the two 
initial intralesional injections had 0.5 ml and the next ones 2.0 ml. 
The injections were applied fractionated into 0.1-0.2 ml portions 
and applied in different areas of the tumor. Clinical parameters 
such as oxygen saturation, body temperature, respiratory 
frequency, cardiac rhythm and blood pressure were checked every 
hour up to 6 h after injections. No changes in such parameters were 
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observed in all the treatment sessions. After the first and second 
sessions, the patient reported occasional temperature increase up to 
38.5º C. In the third session the patient mentioned diffuse hair loss 
and increased sensitivity in the injection areas. In the fourth visit 
he reported some degree of functional dyspnea. 
• June 2017: In agreement with the Oncology and Palliative Care 
Services, it was decided to exclude him from the protocol because 




A 72-year-old man presented in April 2017 with progressing 
unresectable, stage IV malignant melanoma [13]. 
 
I Previous Management 
 
• March 2015: After 3 years presenting melanonychia in the left 
hallux, with persistent inguinal lymphadenopathy, fine needle 
aspiration biopsy of the lymph node indicated the presence of 
melanoma metastasis. One month later and after hallux 
amputation, the diagnosis of stage III nodular melanoma was 
confirmed with Breslow 4.77 mm, Clark level IV, peripheral and 
deep margins compromised, mitotic rate≥ 10, Ki-67 proliferative 
index of 90% and non-mutated BRAF V600. 
• April 2015: Inguinal lymphadenectomy was performed yielding 3 
positive lymph nodes with massive metastases (all capsules 
disrupted). This was followed by radiotherapy (5000 cGy) of the 
perinodal area. 
• June 2015: He started with systemic interferon-α2b. 
• January 2016: Despite the appearance of vitiligo in his left foot 
indicating an immune reaction against melanotic cells, a 
subcutaneous metastatic mass was detected at the hypogastrium 
and the patient was subjected to ipilimumab treatment. 
• July 2016: Due to the lack of response, a series of pembrolizumab 
cycles was performed until being stopped because of pyrexia and 
intestinal infection. 
• November 2016: Following a proximal humeral pathological 
fracture due to bone metastasis, a successful shoulder prosthetic 
replacement after tumor excision was done. Subsequently he 
received 3 cycles of temozolomide. 
• May 2017: Since all the treatments were unable of getting disease 
control, the patient accepted to enter the suicide plus immune gene 
therapy protocol and signed the informed consent. The 18FDG-
PET/CT imaging previous to recruitment displayed multiple lymph 
node, bone, liver and right adrenal metabolically active areas 
compatible with widespread metastases. 
 
II Treatment Course 
 
• June 2017: The patient received five weekly applications of 
subcutaneous vaccine (in the leg) and intralesional suicide gene 
therapy (in the hypogastric mass). As specified in (Table 1), the 
two initial intralesional injections had 0.5 ml and the next ones 2.0 
ml. The injections were applied fractionated into 0.1-0.2 ml 
portions and applied in different areas of the tumor. Clinical 
parameters such as oxygen saturation, body temperature, 
respiratory frequency, cardiac rhythm and blood pressure were 
checked every hour up to 6 h after injections. No changes in such 
parameters were observed in all the treatment sessions. From the 
first to the fourth session, the patient reported occasional 
temperature increase up to 38.5º C after treatment. After the fourth 
session the patient reported diffused hair loss. 
• July 2017: The patient received the treatment two more times every 
other week as described in (Table 1). Neither changes in clinical 
parameters were observed in all the treatment sessions nor pyrexia 
reported after treatment. After seven treatment applications, CT 
analysis confirmed disease progression in axillary lymph nodes, 
lungs, liver and peritoneum. Furthermore, a painful lumbar spine 
metastasis progressed, significantly decreasing the quality of life. 
In agreement with the Oncology and Palliative Care Services, the 
patient was withdrawn from the protocol. Three months later, the 




We report here two cases of advanced melanoma treated with non-viral 
suicide gene therapy and cytokine enhanced vaccines: one mucosal and 
other one cutaneous. Taken into account the advanced status of the 
disease that in both cases was refractory to standard and check point 
immunotherapies, the patients entered the study with an ECOG 
performance status of 2. In this situation the adverse events caused by 
the treatment could be partially hidden by the initial conditions. Anyway, 
we did not register any acute reaction, and the side effects that could be 
attributed to the treatment were from mild to moderate and completely 
manageable: pyrexia, swelling of the injected tumor and partial hair loss 
(alopecia). 
 
Immune-related alopecia was already described in a small proportion of 
melanoma patients (about 1%) receiving immune checkpoints inhibitors 
[14-16]. This side effect could appear delayed after some months from 
the last immunotherapy cycle. This kind of induced alopecia displays 
specific perifollicular lymphocytic infiltrates that affect the functionality 
of hair follicles with the consequent hair loss. Even though both patients 
were subjected to checkpoint inhibition immunotherapy cycles before 
entering the study, the timing of the alopecia onset appearing few days 
after our treatment, strongly suggests that it was probably related to an 
additional immune stimulation triggered by the subcutaneous vaccine. 
This vaccine has not only many melanoma specific antigens but can also 
express immune stimulating cytokines [12]. 
 
Alopecia was also described among the cutaneous adverse effects of 
imatinib that can appear some months after stopping the treatment [17]. 
The patient 1 had been treated with this tyrosine kinase inhibitor after 
the immune check point inhibitors. Therefore, we cannot discard its 
contribution on this side effect. In this exploratory study we found that 
the proposed treatments scheme is feasible in melanoma patients and 
appears to be safe with very mild side effects. Nevertheless, the two early 
patients described in this work entered the study with a very advanced 
stage of the disease precluding the detection of any possible positive 
effect of the treatment. Therefore, we consider that the proposed 
treatment would be more appropriately conducted in a neoadjuvant 
setting, especially before check point inhibitory immunotherapy, as it is 
currently being assayed for conditionally replicating oncolytic 
virotherapies [18]. 
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The successful results obtained in previous veterinary settings together 
with the lack of significant undesirable side effects, encourage the 
completion of further clinical trials to establish the possible clinical 
benefit and safety profile of the proposed approach. 
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